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Despite the rarity of these S mutations, their recogni-
tion has opened up the field of PD research to molecular
attack. Overexpression of wt human S in some trans-
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genic mouse lines results in the development of cyto-Brigham and Women’s Hospital
plasmic S inclusions, loss of dopaminergic synapses,Boston, Massachusetts 02215
and associated motoric impairment (Masliah et al.,
2000). Overexpression of mutant human A53T S in
other transgenic lines produces severe motor deficitsSummary
leading to paralysis and death, in addition to the appear-
ance of insoluble S and Lewy-like inclusions (GiassonAccumulation of misfolded proteins as insoluble ag-
et al., 2002; Lee et al., 2002). Expression of wt or mutantgregates occurs in several neurodegenerative dis-
human S in Drosophila melanogaster leads to Lewy-eases. In Parkinson’s disease (PD) and dementia with
like inclusions in dopaminergic neurons, associated withLewy bodies (DLB), -synuclein (S) accumulates in
neuronal loss and impaired climbing (Feany and Bender,insoluble inclusions. To identify soluble S oligomers
2000). Coexpression in Drosophila of S and the proteinthat precede insoluble aggregates, we probed the cy-
chaperone HSP70 reduces the vulnerability of the dopa-tosols of mesencephalic neuronal (MES) cells, normal
minergic neurons (Auluck et al., 2002).and S-transgenic mouse brains, and normal, PD, and
Despite this compelling evidence for a key role of SDLB human brains. All contained highly soluble oligo-
in the onset of PD pathology in animal models, there ismers of S whose detection was enhanced by delipi-
very little information about its physiological function indation. Exposure of living MES neurons to polyunsatu-
the brain and how a portion of it is gradually convertedrated fatty acids (PUFAs) increasedS oligomer levels,
to highly insoluble inclusions in dopaminergic neuronswhereas saturated FAs decreased them. PUFAs di-
destined to degenerate. S is abundant in the brain,rectly promoted oligomerization of recombinant S.
estimated to constitute1% of total brain proteins, andTransgenic mice accumulated soluble oligomers with
is localized in part to presynaptic terminals. Develop-age. PD and DLB brains had elevated amounts of the
mental studies in songbirds suggest that its expressionsoluble, lipid-dependent oligomers. We conclude that
in certain neurons is associated with the acquisition ofS interacts with PUFAs in vivo to promote the forma-
learning and may thus play a role in synaptic plasticitytion of highly soluble oligomers that precede the insol-
(George et al., 1995). In S knockout mice, a role as auble S aggregates associated with neurodegener-
negative regulator of dopamine neurotransmission wasation.
suggested for S (Abeliovich et al., 2000). Other studies
have suggested that S may function as a chaperoneIntroduction
protein, based on its abundance in cytosol, its natively
unfolded structure, and its prevention of protein aggre-A central unresolved question in the study of human
gation induced by heat shock or chemical treatmentneurodegeneration is how normally soluble neuronal
(Souza et al., 2000).proteins such as tau and -synculein (S) become con-
Although S is principally a soluble, cytosolic protein,verted into highly insoluble, potentially cytotoxic neu-
a portion of it is reversibly associated with membranes
ronal inclusions such as the neurofibrillary tangles of
(Davidson et al., 1998; McLean et al., 2000; Perrin et al.,
Alzheimer’s disease and the Lewy bodies of Parkinson’s
2000; Sharon et al., 2001). The interaction with mem-
disease (PD). A related issue concerns whether such branes appears to be mediated by the 6–7 imperfect
pathological conversions arise in some way from the repeats in its N-terminal region that are homologous to
normal functions of these proteins or rather represent the apolipoprotein-helical region (Perrin et al., 2000). In
entirely distinct toxic properties. Here, we have at- vitro studies suggest that S binds acidic phospholipid
tempted to address these questions in the case of S, vesicles in a way that markedly alters its secondary
which has been implicated at the levels of both genetics structure (Davidson et al., 1998). Moreover, binding and
and biochemical pathology in the pathogenesis of famil- oligomerization of S were enhanced when acidic phos-
ial and sporadic PD. pholipid vesicles were enriched with long-chain PUFAs
S was first associated with PD when a missense (Perrin et al., 2001). In cells treated with high fatty acid
mutation (A53T) in the gene encoding this 140 residue (FA) concentrations, wild-type (wt) and A53T, but not
cytosolic protein was linked to a rare, dominant form of A30P,S accumulated on phospholipid monolayers sur-
PD (Polymeropoulos et al., 1997). Shortly thereafter, S rounding triglyceride-rich lipid droplets (Cole et al.,
was identified biochemically and immunohistochemi- 2002). It was suggested that wt S, but not A53T or
cally as the major constituent of the pathognomonic A30P, may protect stored triglycerides from hydrolysis.
Lewy bodies and the associated neuritic abnormalities Recently, we obtained evidence that S shares some
referred to as Lewy neurites (Baba et al., 1998; Spillantini properties with the family of fatty acid binding proteins
(FABP). We identified regional homologies within S to a
FABP signature motif and showed the ability of purified,*Correspondence: dselkoe@rics.bwh.harvard.edu
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recombinant S to bind radiolabeled oleic acid in a spe- lane 2). In contrast, extraction with a physiologic HEPES/
MgCl2 buffer yielded only the 17 kDa monomer in thecific and stochiometric manner, although with a lower
affinity than classic members of the FABP family (Sharon water-soluble fraction (Figure 1A, lane 1). The S band-
ing pattern after chloroform/methanol extraction ofet al., 2001). Moreover, we detected a pool of cytosolic
S that occurs in high-molecular-weight, lipid-associ- whole brain is highly similar to that observed in the S370
cytosols after extraction of lipids by either chloroform/ated complexes that are detectable only upon lipid re-
moval. Interestingly, LBs have been shown to contain methanol or the fatty acid binding resin, Lipidex1000,
or after heat treatment at 65C (Sharon et al., 2001). Thelipids (den Hartog Jager, 1969; Gai et al., 2000), in addi-
tion to S and other proteins. It is therefore important detection of these larger S species directly after lipid
removal by chloroform/methanol but not in aqueousto examine the potential role of lipids in the genesis and
modulation of PD-type neuropathology. buffer extracts (Figure 1A) suggests that S oligomers
exist in complexes with lipids in the brain but cannotWe now describe the existence of highly soluble S
oligomers in human S-expressing mesencephalic neu- be detected by Western blotting unless the S epitopes
are first exposed by lipid removal.ronal cells, in the brains of normal and S transgenic
mice, and in the brains of humans with PD and the Determination of the apparent molecular weights of
the ladder of S-reactive bands strongly suggested thatrelated disorder, Lewy body dementia (DLB). We show
that the oligomerization process is directly regulated by they are, in fact, oligomers. The bands migrate on dena-
turing SDS gels at 17 kDa (monomer), 35 kDa (predictedcellular fatty acid levels, with specific enhancement by
polyunsaturated FAs and inhibition by saturated FAs. dimer,34 kDa), 53 kDa (trimer,51 kDa), 71 kDa (tetra-
mer, 68 kDa), 84 kDa (pentamer, 85 kDa), and 105The oligomers are of disease relevance in that they are
augmented in the neuronal cytoplasm in both PD and kDa (hexamer, 102 kDa) (Figure 1B). Importantly, this
fine delineation of the individual bands is only observedDLB patients, compared to age-matched control sub-
jects. Moreover, they appear earlier and accumulate to when samples have first been exposed to delipidating
agents such as chloroform/methanol or Lipidex1000, ina greater extent in A53T than wt S-expressing mesen-
cephalic neuronal cells, and they accumulate with age combination with heat treatment at 65C. In the case of
living cells, delipidation can also be achieved by growingin transgenic mouse brains. We conclude that soluble,
metastable oligomers of S that are induced by certain the cells in the absence of serum for 16 hr (e.g., Figure
1B). Without delipidation, the bands run as a poorlyFAs and exist in the high-speed cytosol represent a
very early aggregated form of the protein that occurs focused immunoreactive smear throughout the middle
and upper portions of the gel. To obtain further supportnormally in small amounts but can gradually transition
in vivo to much larger, insoluble polymers. for their identity as oligomers, we attempted to separate
the individual bands by isolelectric focusing on two-
dimensional gels. Both the monomer and the higher
species migrated at the same isoelectric point of 4.0Results
(the calculated isoelectric point for S is 4.6) on SDS
denaturing gels (Figure 1C), strongly supporting the con-Stable Oligomers of S Occur in a Lipid-
Associated Form in the High-Speed clusion that the modification of S that produces these
additional species is oligomerization.Cytosol of Brain Tissue
S is a highly soluble,17 kDa cytoplasmic protein that
nevertheless forms insoluble, high-molecular-weight The S Oligomers Occur In Vivo
(MW) aggregates in the neurons of older humans. We The detection of the soluble S oligomers appears to
reasoned that this conversion would begin with the for- depend on delipidation using chloroform/methanol,
mation of small, diffusible oligomers of S that are en- heat, or Lipidex1000 combined with heat (above data
tirely soluble. On this basis, we previously searched for and Sharon et al., 2001). In addition to delipidating pro-
and identified stable S-immunoreactive species mi- teins, such treatments can partially denature proteins,
grating at 35 kDa and above in the very high speed and this could conceivably lead to some oligomerization
(post-370,000  g) cytosols (S370) of mesencephalic occurring in vitro. It was therefore important to confirm
(MES) neuronal cells and human and mouse brains the in vivo existence of the soluble oligomers in neuronal
(Sharon et al., 2001). We designate these S-reactive cells and brain without the use of potentially denaturing
species as buffer-soluble oligomers to distinguish them conditions. To this end, we carried out size exclusion
from soluble protein complexes containing S and other chromatography (SEC) of the high-speed soluble frac-
proteins (Xu et al., 2002) and from buffer-insoluble, tions (S370) of S-expressing MES cells and fresh
highly aggregated S species (Baba et al., 1998; Hashi- mouse brains under entirely nondenaturing conditions,
moto et al., 2001; Kahle et al., 2001; Spillantini et al., i.e., in physiological buffer. The Sephadex G75 columns
1998). To further elucidate the relationship of these solu- used gave linear elution profiles of a set of protein stan-
ble oligomers to brain lipids, we directly extracted whole dards having MWs of 1 to 70 kDa (Figures 2A and
mouse brains in chloroform/methanol (2:1), a method 2B). The largest amount of S species in the S370 cyto-
previously used to purify myelin basic protein and other sol eluted in SEC fractions corresponding to 40–65
lipid-associated proteins from brain (Eylar et al., 1969; kDa; smaller amounts were present in flanking fractions,
Oshiro and Eylar, 1970). This extraction of lipids revealed yielding a full size range of 30 kDa to 70 kDa (the
both the 17 kDa S monomer and abundant higher MW void volume) (Figures 2C–2F). When each SEC fraction
S-immunoreactive bands migrating at 35 kDa and was directly run on SDS-PAGE gels and Western blotted
(without heating), almost all of the S-immunoreactiveabove in the residual, water-soluble material (Figure 1A,
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Figure 1. S Occurs in Lipid-Associated, Soluble Oligomers in Normal Mouse Brain and in S-Transfected MES Cells
(A) Chloroform/methanol extraction reveals S-reactive oligomeric species in whole mouse brain. Normal mouse brain (20 g) was extracted
in HEPES-MgCl2 buffer containing 1% NP-40 (lane 1) or in chloroform/methanol (2:1) (lane 2), and the aqueously soluble fractions in each
case were analyzed by Western blotting with H3C. The three very faint bands migrating at 70–100 kDa in lane 1 are nonspecific. The vast
majority of S immunoreactivity throughout lane 2 is S specific, i.e., disappears upon antibody absorption (not shown).
(B) Apparent MWs of the cytosolic S species suggest that they are oligomers. Human wt S-transfected MES neurons were conditioned in
the absence of serum and presence of FA-free BSA (to assist delipidation). Samples of high-speed cytosol (15 g) were incubated at 65C
overnight and then Western blotted with LB509. The relative migration of S-specific bands was calculated using a BenchMark prestained
protein ladder and AlphaEase (version 5.5) software. 2X through 6X indicate multiples of the monomer (1X).
(C) S monomers and higher MW species migrate to the same isoelectric point, supporting the identity of the later as oligomers. High-speed
cytosol (10 g) of human wt S transfected MES cells was incubated at 65C overnight and than subjected to isoelectric focusing (IEF) (pH
gradient, 3 to 10) followed by SDS-PAGE (8%–16% Tris-Glycine gradient). The 2D gel was blotted with LB509.
protein appeared at the monomer position (17 kDa) Polyunsaturated Fatty Acids Promote and Saturated
Fatty Acids Inhibit the Formation of Soluble Son the gel (Figures 2C and 2E). However, if these blots
were incubated at 65C just before development, the Oligomers in Living Mesencephalic Neurons
Both chloroform/methanol and Lipidex extractions re-SEC fractions were shown to contain S dimers (35
kDa) and some higher oligomers, in addition to the mo- veal the SDS-stable S oligomers in brain tissue, sug-
gesting the association of the oligomers with lipids.nomers; the detection of the latter was also markedly
enhanced (Figures 2D and 2F). The S370 fractions from Moreover, we previously identified sequences near the
N and C termini of S that are homologous with a con-mouse brain tended to have slightly larger S species
(range 30 to 70 kDa) than those of MES cells (range served motif of the fatty acid binding protein (FABP)
family (Sharon et al., 2001). These findings led us to20–45). We obtained closely similar results by per-
forming SEC on pure, recombinant human S (data not ask whether the formation and stability of soluble S
oligomers are regulated by FAs in intact cells. We sup-shown). These SEC fractionation and sizing results dem-
onstrate that dimers and higher oligomers of S occur plemented the conditioned medium of MES cells stably
expressing wt human S with specific FAs. In thesein the high-speed soluble fraction of both S-expressing
MES cells and normal mouse brain in the absence of a experiments, BSA was used as a vehicle to introduce
the FAs into the cells (at a BSA:FA ratio of 1:5) (Bonendenaturing treatment. Moreover, soluble S oligomers
that have been gel-separated and fixed onto mem- et al., 1999; Schaffer and Lodish, 1994). MES cells grown
overnight in serum-free medium supplemented with FA-branes are not detected well unless the membranes
are exposed to heat, a treatment that may remove S- free BSA served as the control condition to establish
basal levels of S oligomers in the high-speed (S370)associated lipids to expose S epitopes (see Discus-
sion). When we heated the SEC fractions at 65C before cytosol. In parallel, sister cultures were grown overnight
in serum-free medium supplemented with BSA plus spe-gel electrophoresis/Western blotting, the heating again
increased the amounts of oligomers as well as mono- cific FAs. After overnight incubation, the S370 samples
were blotted for S oligomer content. Because the totalmers detectable on the blots, similar to the result ob-
tained if the unheated fractions were run and then the FA concentration in normal human plasma is about 500
M, we initially used this concentration for either FAblots were heated (data not shown). Thus, the invariant
increase, rather than decrease, in monomer levels that mixtures or individual FAs. As this would represent a
high concentration for an individual FA, we subsequentlyaccompanies the increase in oligomers upon heat treat-
ment indicates that the soluble S oligomers do not used concentrations as low as 35 M and obtained
indistinguishable results. Analysis of the S pattern inresult from in vitro aggregation of the monomer but
rather exist as such in the high-speed cytosols of MES wt S transfected cells indicated that while monoun-
saturated fatty acids (oleic acid [18:1] or eicosenoic acidneurons and brain tissue.
Neuron
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Figure 2. Soluble S Oligomers Occur In Vivo
(A) Elution pattern of a Sephadex G75 SEC column established using the indicated proteins as size markers. The column was eluted with 50
mM ammonium acetate (pH 7.4), at 15 ml/hr. One milliliter fractions were collected and assayed for protein content. Protein size markers:
void70 kDa, fractions 10–15; bovine serum albumin (BSA) 66 kDa, fractions 16–19; ovalbumin (OA) 44 kDa, fractions 19–22; chymotrypsinogen
A (CTA) 27.5 kDa, fractions 25–29; myoglobin (MG) 17.5 kDa, fractions 32–35; ubiquitin (ub) 8 kDa, fractions 36–40; vitamin B12 (B12) 1.3 kDa,
fractions 45–53.
(B) The elution pattern of the protein size markers was linear on a semi-log plot, indicating efficient column separation. SEC conditions and protein
size markers as in (A). Graph presented as log MW to Kav (Ve  Vo/Vt  Vo, where Ve  elution vol, Vo  void vol, Vt  total column vol).
(C) S reactivity of SEC fractions of S370 cytosol (1.5 mg protein starting sample) from normal mouse brain. Fractions were loaded on 8%–16%
Tris-Glycine SDS-PAGE without any heat treatment and the PVDF blot was stained with ab H3C. m, monomer; d, dimer.
(D) S reactivity of same SEC fractions as in (C), but the PVDF blot was incubated at 65C before S immunostaining. Note that oligomers
are now detectable in the 40–65 kDa SEC fractions (lanes 21–17), and monomer detection is also enhanced.
(E) Blots shown in (C) and (D) were quantified for the relative amount of S monomer in each fraction normalized to a standard amount (50
ng) of purified, recombinant human S run on the same blot (far right lanes in C and D). Gray bars, results from standard Western blots (C);
black bars, results from blots preincubated at 65C before immunostaining (D).
(F) As in (E), but quantification of the S dimer alone.
[20:1]) had no effect on the levels of S oligomers in the excluded material (Figure 3A). When carbon chain length
was held constant, there was a direct correlation be-S370 cytosol compared to BSA alone, conditioning the
cells in saturated FAs (stearic acid [18:0] or arachidic tween the degree of unsaturation (number of double
bonds) and the level of S oligomerization; the moreacid [20:0]) resulted in a striking and consistent decrease
in the levels ofS oligomers, without appreciably chang- unsaturated the FA was, the more effective it was in
promoting the appearance of S oligomers (Figure 3A).ing monomer levels (Figure 3A). In contrast, otherwise
identical conditioning in polyunsaturated FAs (PUFAs) Longer carbon chains were also associated with in-
creasing levels of S oligomers. PUFAs ranging from 18(-linolenic acid [ALA] [18:3] or eicosapentaenoic acid
[20:5]) dramatically enhanced the levels of S oligomers, to 22 carbons were added to the media of the wt S-
expressing MES cells at concentrations of 500 M.including high MW species that extended into gel-
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Figure 3. FAs Regulate the Extent of S Oligomerization in the Cytosol of Living MES Cells
(A) S oligomerization is differentially affected by the degree of FA saturation. High-speed cytosols (15 g protein) of human wt S stable
MES cells conditioned in the presence of the indicated FA/BSA complexes (500/100 M) in serum-free medium. Samples were treated at
65C overnight prior to gel loading and blotting with LB509. Samples are run in duplicate; each lane represents a separate dish (sister culture)
treated and processed in parallel. 18:0, stearic acid; 18:1, oleic acid; 18:3, -linolenic acid; 20:0, arachidic acid; 20:1, eicosenoic acid; 20:5,
eicosapentaenoic acid. Right arrow, position of the resolving/stacking gel interface.
(B) Longer carbon chains are more effective in promoting S oligomerization. High-speed cytosols (15 g) of human wt S transfected cells
conditioned and analyzed as in (A). 18:2, linoleic acid; 20:2, eicosadienoic acid; 18:3, -linolenic acid; 20:3, eicosatrienoic acid; 20:4, arachidonic
acid; 22:4, docosatetraenoic acid.
(C) Dynamic nature of S oligomerization in MES cells conditioned with -linolenic acid (18:3). Human wt S-transfected MES cells were
conditioned with 18:3 for the times (h) indicated at the top of each lane and analyzed as in (A). “0” hr lanes are sister cultures conditioned in
BSA alone (i.e., FA-free) for the longest incubation time tested (18 hr). The stable MES clone used in (C) was under cultivation longer than
the one used in (A), resulting in increased high MW polymeric S in the former (see Figure 5 and Results).
Comparisons were made of the following pairs: 18:2 and peroxisomes or else used for synthesis of lipids.
FAs are assumed to cross cell membranes continuously,versus 20:2; 18:3 versus 20:3; and 20:4 versus 22:4 (Fig-
ure 3B). In each case, the longer chain PUFA enhanced either actively by protein transporters or via flip-flop
of the FA through the membrane (Hamilton, 1999). Wethe levels of soluble dimers and oligomers more po-
tently. The effect of carbon chain length was less pro- therefore asked how soon after a cell is exposed to
extracellular FA can the enhancement ofS oligomeriza-nounced than that of degree of saturation. Nevertheless,
densitometric analyses confirmed that the oligomer lev- tion be observed. We assumed that a rapid response
might suggest that S was reacting to the FA itself,els rose about 2-fold within each pair we compared (not
shown). whereas a delayed response might suggest that it was
reacting to a FA metabolite or complex lipid molecule.
Cells were incubated with -linolenic acid (ALA [18:3])The Effect of Fatty Acids on S Oligomerization
Is Time Dependent in their conditioned media for the time periods indicated
in Figure 3C. We initially used a high concentration (500In cells, FAs are bound mainly to membranes and to
FABPs, when these are present (Hamilton and Kamp, M) and then examined low concentrations (35 M),
with the latter yielding closely similar results. Cells were1999). Free cytosolic FA concentrations are generally
low, i.e., in the nM range. A principal force keeping them harvested, and equal protein amounts of S370 cytosols
were incubated at 65C and Western blotted. The levelslow is the formation of a thioester linkage between the
FA carboxyl group and the thiol group of Coenzyme A of both S monomers and oligomers, particularly di-
mers, rose within 1 hr after adding PUFA to the cultures(yielding fatty acyl-CoA) within minutes after a FA enters
a cell (Nelson and Cox, 2000). The esterified FAs are (Figure 3C). A further increase in the amount of S oligo-
mers occurred with time up to 6 hr. However, an oppo-then consumed for energy production by mitochondria
Neuron
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Figure 4. Polyunsaturated FAs Induce the Oligomerization of Purified, Recombinant Human Wild-Type S In Vitro
(A) 2.0 M purified S was incubated without or with docosahexaenoic acid (DHA, 22:6) at the indicated concentrations at 37C for 2 or 48
hr. Samples (75 ng protein) were Western blotted with H3C without any 65C treatment.
(B) Same as in (A), but analysis by silver staining of samples of 500 ng protein each.
(C) S oligomerization in response to PUFA treatment in stably transfected MES cells is closely similar to that of pure S protein in vitro (A).
Human wt S MES cells were conditioned with 500 uM ALA (20:3) for the indicated times (h). High-speed cytosols were treated and analyzed
by Western blot as per Figure 3A. M, monomer; D, dimer; T, trimer.
site trend was found in cells incubated with ALA for 18 asked whether the oligomer-promoting effect of FAs
was direct or was a side product of FA peroxidation.hr. We observed a reduction in the intensity of the S
oligomers, while the amount of very high MW and gel- As one method of assessing this, we used a naturally
occurring oxidized PUFA, 13-hydroxy octadecadienoicexcluded immunoreactive material rose sharply. The
gel-excluded material represents high MW aggregated acid (13-S-HODE), an enzymatically oxidized form of
linoleic acid (18:2). 13-S-HODE was no more potent inS species that are no longer SDS soluble. Thus, S
responds in a dynamic fashion to the introduction of a inducing oligomers than the parental, nonoxidized 18:2
(data not shown). As another approach, the MES cellsspecific FA into the MES cell, with the initial rapidity of
the response raising the possibility of a direct FA effect were conditioned with or without PUFAs under either
oxidizing conditions (33 or 100 M H2O2) or reducingon S (see below).
By quantitative Western blotting, the levels of both conditions (33 or 100 M thioctic [-lipoic] acid). We
observed no difference in the oligomer-promoting effectS monomers and total S immunoreactive species (in-
cluding gel-excluded aggregated material) were mark- of a PUFA (18:3) between these two conditions (data
not shown).edly increased in the cytosol of MES cells after overnight
exposure to PUFAs. The average increase was 300-
fold and ranged from 50- to 500-fold, depending on Fatty Acids Bind to Purified S and Directly
Promote Its Oligomerization In Vitrothe particular clonal S cell line being examined and
its time under cultivation (note that total S oligomer The striking effects of physiological levels of PUFAs on
the amount of soluble S oligomers we observed incontent changes with the time of cultivation [see below]).
We hypothesized that these PUFA-induced rises were living cells raised the question of whether the FAs have
direct or indirect effects on S. We previously found thatdue to the increased formation of soluble oligomers and/
or to conformational changes in monomers and oligo- purified, recombinant human S could bind radiolabeled
oleic acid (14C 18:1) in a stochiometric manner in vitromers that enhance antibody recognition. To exclude the
alternative possibility of transcriptional activation by the (Sharon et al., 2001). We now asked whether the direct
binding of S to FAs promoted its oligomerization. Puri-PUFAs, we conducted quantitative Northern blotting for
S. This revealed no changes whatsoever in cellular S fied, recombinant human wt S (2.0 M) was incubated
at 37C with increasing concentrations of decosohexa-mRNA levels in response to overnight PUFA incubation
(data not shown). noic acid (DHA; 22:6), and aliquots were analyzed by
SDS-PAGE after varying intervals of incubation (FigureBecause PUFAs are a target for lipid peroxidation, we
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Figure 5. Mutant A53T S-Expressing MES Cells Accumulate Soluble Oligomers Earlier than Do Wild-Type S Transfectants
(A) Wild-type S expressing MES cells. Samples of high-speed cytosols (15 g protein) collected at increasing intervals post DNA-transfection
were treated at 65C overnight and Western blotted with LB509.
(B) A53T S expressing MES cells were processed identically as in (A).
(C) Higher relative levels of soluble S oligomers accumulate in A53T than in wt transfectants over time. Blots from (A) and (B) were scanned
and quantified (Sharon et al., 2001). Values at the y axis represent the ratios of quantitative densitometry of S oligomers (migrating at 35
kDa and higher) to monomers (migrating at 17 kDa) for each time point.
4). After 2 hr incubation without FA, the S was only ing at 48 hr. Several different PUFAs were tested for
their ability to mediate the oligomerization of pure S.detectable in monomeric form, as confirmed on both
silver stains and Western blots (Figures 4A and 4B, ex- In general, the longer and more unsaturated FAs were
the most potent, with a rank order of 22:6  20:4 treme right lanes). In contrast, a 2 hr incubation with
DHA clearly promoted oligomerization of pure S at 18:3  18:0 (data not shown), reflecting the results ob-
tained with living MES cells (Figure 3).concentrations of the PUFA as low as 10 M, whereas
incubations in 1 M or 5 M were without significant We also conducted in vitro FA incubation studies on
pure S that had first been subjected to size exclu-effect. S oligomerization was enhanced by DHA in a
dose-dependent fashion between 10 and 1000 M (Fig- sion chromatography. Beginning with the SEC-purified
monomer alone, we were able to show unequivocallyures 4A and 4B). Importantly, in the case of purified S,
there was no need for heat treatment in order to detect that it oligomerizes in the presence of PUFAs, thereby
excluding the remote possibility that the PUFAs werethe oligomers by Western blotting. The dimer (35 kDa)
of pure S observed by silver staining after incubation disaggregating some hypothetical higher MW S aggre-
gates (data not shown).with DHA at 10 M migrated at the same position as
the presumptive dimers we had identified by Western
blotting in intact S-transfected MES cells incubated Soluble S Oligomers Accumulate More Rapidly
in Cells Expressing A53T Mutant Human Swith PUFA (Figure 4C). Incubation of pure S with PUFA
not only promoted its oligomerization but was also asso- To explore the relevance of the soluble S oligomers
described above to the pathogenesis of -synucleino-ciated with the detection of increased (rather than de-
creased) levels of monomeric S by Western blotting pathies like PD, we compared MES neuronal lines stably
expressing wt or A53T mutant human S. Five different(Figure 4A). In addition, SDS sample preparation and
subsequent SDS-PAGE never led to in vitro oligomeriza- matched pairs of wt and A53T clones were compared
for soluble high MW S immunoreactivity accumulatingtion of pure S monomer (e.g., Figures 4A and 4B, ex-
treme right lanes). These findings again support the con- with time in culture; a representative pair of clones is
shown in Figure 5. The clones were matched for closelyclusion that the highly soluble S oligomers we detect
in the cytosols of MES neurons and brains exist in vivo. similar expression levels of S monomer and were main-
tained identically under normal serum conditions fromWe next examined the effects on the oligomer pattern
of incubating pure S in DHA for prolonged periods. the time of initial DNA transfection through selection of
stable clones and then serial passage in culture. S370After 48 hr, the overall level of oligomeric species de-
tected by Western blotting was increased (compared to was prepared at increasing time points posttransfection;
equal protein aliquots were incubated at 65C, electro-2 hr) in samples containing 100 or 1000 M DHA (Figure
4A). In particular, more high MW (35 kDa) oligomers phoresed in parallel, and Western blotted for S mono-
mers and oligomers. Early during clonal lifetime (63 daysextending up the running gel were observed, and this
change was accompanied by less monomers and di- posttransfection), the content of human S oligomers
was very low in the wt clones but was already apprecia-mers than were seen at 2 hr. These Western blot changes
were generally reflected by the less sensitive method ble in the matched A53T clones (compare Figures 5A
and 5B). Thereafter, both the wt and A53T clonesof silver staining, in which the dimer was far less visible
at 48 hr than at 2 hr at DHA concentrations of 10, 50, showed first a time-dependent accumulation and then
a loss of oligomers. We quantified the ratio of all S-and 100 M (Figure 4B). At the highest FA concentration
(1000M), the trimer band became visible by silver stain- reactive species 35 kDa (oligomers) to the 17 kDa
Neuron
590
Figure 6. Age-Dependent Accumulation of
Soluble S Oligomers of Both Transgenic Hu-
man S and Endogenous Mouse S in Brain
Duplicate samples of high-speed superna-
tants of young (4 week, n  3) or old (18
month, n  3) mice were incubated at 65C
and then blotted with (A) H3C (20 g protein)
for total S or (B) LB509 (50 g) for human
S only. To verify specificity, each antibody
was absorbed with 10 g purified recombi-
nant S. Monomer (M), dimer (D), and immu-
noreactive oligomers of 85 kDa (bracket)
are all S specific. n, nonspecific band.
species (monomers) (Figure 5C). This ratio was far higher wt tg S (LB509) as well as for endogenous mouse S
(H3C) (Figure 6). We confirmed the specificity of thisin the A53T- than wt-expressing clones already at the
earliest posttransfection time point we measured (63 high MW S reactivity, by showing the same patterns
with the additional antibodies 15G7 (human-specific)days). (Earlier time points could not be taken, because
it took60 days to select stable clones after DNA trans- and syn-1 (both mouse and human S) (data not shown).
We also preabsorbed each antibody with purified, re-fection.) There was further accumulation of oligomers
over time in both the wt and A53T clones, but the maxi- combinant S (Figures 6A and 6B). Both the dimer and
the high MW smear at 85 kDa and above was S-mal oligomer:monomer ratio was reached somewhat
earlier in the case of the A53T clones. After 100 days specific, whereas a25 kDa band appearing in the older
mice was nonspecific.in culture, we observed a striking decline in total S
levels, with the oligomers declining more rapidly than
the monomers, resulting in falling ratios. This decline is
related to the overall loss of S expression that we Accumulation of Soluble S Oligomers in Human
Brains with Synucleinopathiesreported previously in stable MES transfectants (Sharon
et al., 2001). We did not detect a significant difference Finally, we asked whether the accumulation of soluble
S oligomers in MES neurons and mouse brains de-between wt and A53T clones as regards the time interval
until complete loss of S expression (for monomers as scribed above was reflected in similar changes in human
brain. Cerebral cortex from five brains each of PD, DLB,well as oligomers).
and age-matched normal subjects (15 brains total) were
analyzed by quantitative Western blotting. We assayedAge-Dependent Accumulation of Soluble S
Oligomers in Mouse Brain the high-speed (S370) cytosols and also a lipid-rich,
low MW “floating” fraction, both prepared as previouslyTo determine whether the above data in mesencephalic
neurons reflect changes in S that occur in vivo, we described (Sharon et al., 2001). To adjust for varying
absolute levels of S among the different brain samples,assessed soluble oligomer levels over time in human
S transgenic (tg) mouse brains (Sharon et al., 2001) we expressed the results as a ratio between the levels
of 35 kDa (dimeric) and 17 kDa (monomeric) S mea-and compared these to the pattern of endogenous S
in the same mice. Equal protein aliquots of S370 super- sured in the same sample (i.e., the same gel lane). In
the high-speed cytosols, S monomers, dimers, andnatants from young and old tg brains were incubated
at 65C and then analyzed by Western blotting. To detect some higher MW oligomers were detected after incuba-
tion at 65C (Figure 7A). We observed a significant 2-solely the human S protein, we used antibodies LB509
and 15G7, whereas for total S (endogenous mouse fold increase in the 35/17 kDa S ratio in the cytosols
of both PD and DLB brains, compared to that in simulta-plus transgenic human), we used antibodies H3C and
Syn-1. Comparisons with non-tg littermates revealed neously analyzed controls (Figure 7D) (p 	 0.005 for PD
and p 	 0.01 for DLB). The detection of the higher MWthat the level of brain expression of human S was about
a half of that of endogenous mouse S (not shown). We oligomers was strongly enhanced by incubating the cy-
tosols with the fatty acid binding resin, Lipidex1000, atfound that brain levels of S monomers were similar for
young (4 week) and old (18 month) mice. Using H3C 65C and analyzing the material that was bound to the
Lipidex, as previously reported (Figure 7B; Sharon etantibody, we detected a modest accumulation of the
dimer in old compared with young mice (Figure 6A). The al., 2001). In the case of the lipid-rich, low-speed fraction
of brain homogenates that floats above a sucrose cush-dimer was not observed with antibody LB509, probably
due to its low abundance (Figure 6B). However, substan- ion, we extracted this fraction in chloroform/methanol
(2:1) and then Western blotted the residual water-solubletial differences between young and old mice were de-
tected in the higher MW S species. In the older mice, material. Here, we observed very high MW S-immuno-
reactive material migrating only in the stacking gel downwe observed accumulation of soluble S oligomers,
specifically accumulation of a 85 kDa band and a to its interface with the resolving gel, and this was con-
sistently present in the PD and DLB samples but absenthigher immunoreactive smear migrating up to the gel-
excluded region. This pattern was observed for human in the controls (Figure 7C).
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Figure 7. Accumulation of Soluble S Oligo-
mers in PD and DLB Human Brains
(A) Soluble S oligomers in human brain.
High-speed supernatant samples (20 g)
from a representative case each of control
(n  5), PD (n  5), and DLB (n  5) brains
were incubated at 65C and blotted with
LB509.
(B) Detection of soluble S oligomers is en-
hanced by the FA binding resin, Lipidex1000.
Supernatant samples as in (A), but treated
with Lipidex1000 (Sharon et al., 2001). The
material that bound to Lipidex was then blot-
ted with LB509.
(C) Insoluble (gel-excluded) S aggregates in
PD and DLB brains. Chloroform/methanol ex-
traction of the lipid-rich, low-speed fraction
(Sharon et al., 2001) of the brains shown in
(A) and (B). Equal volumes (50 l of a total 500
l suspension) were extracted in chloroform/
methanol (2:1). The interface between the organic (lower) and aqueous (upper) fractions was resuspended in 2X Laemmli buffer (Sharon et
al., 2001) and blotted with LB509. Arrow, position of the resolving/stacking gel interface. Insoluble S aggregates are present in the stacking
gel only and do not enter the resolving gel.
(D) Dimer levels in PD and DLB brains are significantly more abundant than in controls. Densitometry ratios of 35 kDa dimer to 17 kDa monomer
for control, PD, and DLB brains (n  5 each). Control to PD comparison, p 	 0.005; control to DLB comparison, p 	 0.01 (two-tailed equal
variance t test).
Discussion to be age-dependent, in that younger mice had substan-
tially less oligomers than older mice. This trend obtained
for both transgenic human S and endogenous mouseNumerous human neurodegenerative diseases are de-
fined pathologically by the presence of highly insoluble S. Moreover, in the human synucleinopathies PD and
DLB, there is a pronounced accumulation both of solu-inclusions of protein aggregates within characteristic
neuronal populations. In the case of PD, DLB, multiple ble S oligomers in high-speed brain supernatants and
of gel-excluded S aggregates that are revealed by ex-systems atrophy, and related disorders, the prototypical
inclusions are the Lewy bodies, composed in large part tracting the lipid-rich fraction of brain with chloroform/
methanol. The various properties of the oligomers de-of insoluble filaments of S. For many years, there has
been controversy about whether such inclusions are a scribed here suggest that they represent an early, still
soluble but detergent-stable assembly form of S thatcause or an effect of the neuronal degeneration. This
debate has recently begun to be resolved by the recog- has direct relevance to human synucleinopathies.
We use the term soluble oligomers based on theirnition that the large inclusions are in equilibrium with
much smaller, diffusible oligomeric assemblies that may presence in a very high-speed (post-370,000 g) super-
natant. Protofibrils or fibrils of S would not be presentbe able to induce cell injury. If this emerging hypothesis,
which appears relevant to PD, Alzheimer’s disease, Hun- in the S370, because these would sediment at lower
forces (	100,000  g), as has been reported for bothtington’s disease, and several other disorders, is cor-
rect, then a major mechanistic and therapeutic objective S protofibrils (Kahle et al., 2001) and A
 protofibrils
(Walsh et al., 2002).is to identify and inhibit the earliest soluble oligomers
of the protein, arising well before the formation of insolu- We performed size exclusion chromatography to
demonstrate that the soluble S oligomers exist in vivoble, microscopically visible aggregates.
Here, we define and characterize a normal cellular and do not result from in vitro aggregation of S mono-
mer induced by the 65C treatment and SDS-PAGE thatpool of entirely soluble S oligomers whose formation
and stability are regulated by saturated and polyunsatu- we use to immunodetect them. Both dimers and higher
oligomers were separated by SEC performed in physio-rated fatty acids. Importantly, the soluble S oligomers
are detectable in the very high-speed cytosols of mesen- logical buffer, and they eluted in fractions clearly corre-
sponding to sizes greater than monomer (Figure 2). Fur-cephalic neuronal cells, mouse brains, and human
brains. The detection of these SDS-stable, soluble inter- thermore, after the SEC fractions were electrophoresed
(without any heating) and fixed to PVDF membranes,mediates by Western blotting depends on protocols that
include a delipidation step. In this regard, we applied heating these membranes to 65C enhanced the detec-
tion of both oligomers and monomers in a step thatthe chloroform/methanol extraction method (Sharon et
al., 2001) to remove lipids from S-oligomers and enable could not allow further aggregation of the monomers.
Heat and delipidation (Lipidex; chlorform/methanol)their detection by antibodies. We further show that the
soluble S oligomers accumulate with time in the cyto- treatments that reveal the soluble oligomers are invari-
ably associated with detection of more, rather than less,plasm of cultured mesencephalic dopaminergic cells
and that this accumulation is accelerated by expressing monomers, further obviating the possibility that these
treatments are inducing S aggregation in vitro. More-the PD-causing A53T mutation. In accord, the appear-
ance of soluble S oligomers in mouse brain was found over, SDS solubilization of S370 samples and denaturing
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gel electrophoresis was never found to induce the oligo- cluded a pretreatment (Lipidex1000 extraction) aimed
at removing lipids, especially FAs, from the purified re-merization of either the natural or recombinantS mono-
mers. Rather, SDS-PAGE of fractions eluting from the combinant S protein prior to its incubation with FAs.
This may make S more able to bind FAs at lower con-SEC column at35 kDa (dimers and oligomers) appears
to induce partial depolymerization of these metastable centrations and at a faster rate. The oligomerization
of S has also been observed in cellular experimentsoligomers to release monomers (Figure 2).
In view of the ability of lipid extraction to markedly utilizing chemical crosslinking with the reducible cross-
linker DTBP (Cole et al., 2002). On this basis, Cole andenhance the detection of soluble S oligomers in the
cytosol, we asked whether their formation and/or stabil- coworkers suggested thatS exists in cells in an equilib-
rium of monomers and oligomers and that the crosslink-ity were regulated by the fatty acid content of a cell.
Conditioning intact MES neurons with physiological ing stabilized existing oligomers. These findings are
compatible with our own, although we did not require(plasma) levels of different fatty acids revealed that
PUFAs promote the appearance of oligomers in the cy- crosslinking to detect a population of SDS-metastable
oligomers in our cell and brain cytosols. One differencetosol in a time-dependent fashion. Increasing the extent
of unsaturation of the FA strikingly enhanced the between the two studies is the cell lines used: we studied
MES cells with dopaminergic properties, whereas Coleamounts of soluble S oligomers detected in the treated
cells. Conversely, MES cells conditioned with fully satu- and coworkers examined HEK293 cells. This difference
raises the possibility that certain cell-specific factors inrated FAs consistently showed lower amounts of soluble
S dimers and oligomers than those exposed to mono- dopaminergic neurons might help to promote or stabilize
S oligomers. In this regard, recent findings suggest aunsaturated FAs or to the BSA carrier protein alone. We
obtained evidence that these regulatory effects repre- positive role for PUFAs in the maintenance of dopamine
levels and the amounts of dopamine-containing lipidsent, at least in part, a direct action of the FAs on S
by incubating purified human S in vitro with DHA. This vesicles in neurons (Zimmer et al., 1998, 2000).
Based on our collective findings, we speculate thatresulted in the dose- and time-dependent formation of
SDS-stable oligomers of the pure protein, similar to S monomers interact in the neuronal cytoplasm with
FAs, and that certain FAs, particularly longer and morethose observed for nativeS in the cytosols of the PUFA-
treated MES cells, in S transgenic mouse brains, and unsaturated molecules, help mediate the formation of
early, soluble oligomers. The oligomers appear to existin the brains of humans with PD or DLB.
In our in vitro assays, we observed the de novo ap- normally in small amounts; however, over time (i.e., dur-
ing aging) or with prolonged exposure to PUFAs in thepearance of dimers and trimers of pure S within 2 hr
of incubation with PUFA (Figure 4), and in intact dopa- neuronal cytoplasm, a portion of them may aggregate
into much larger, insoluble assemblies, as we observedminergic mesencephalic cells, the oligomers began ac-
cumulating within 1 hr after supplementing the medium in both mesencephalic neurons and transgenic mice.
According to this hypothetical model, the ability of Swith PUFAs (Figure 3C). Further, our results indicate that
the transition from soluble to insoluble (gel-excluded) to interact with FAs in the cytoplasm, during which a
portion of S is converted into highly soluble, lipid-asso-oligomers is also FA dependent. At early time points
(1–6 hr) of incubation with ALA, there was clear enhance- ciated oligomers, may constitute part of the physiologi-
cal function of the protein. We base the latter assump-ment of the soluble oligomers (migrating at 35 to 120
kDa), but after longer incubation times (18 hr), there was tion on the following observations: (1) soluble oligomers
of endogenous S appear in normal mouse brain asa major reduction in these oligomers but an increase in
S-reactive gel excluded material (Figures 3A–3C). We early as 3 weeks of age; (2) soluble oligomers respond
very rapidly to changes in the lipid environment, beinghypothesize that this gradual progression in the size
and insolubility of S assemblies represents an analog induced in intact MES neurons after just 1 hr of incuba-
tion in physiological extracellular concentrations ofof the changes in S solubility and aggregation state
reported in PD and other synucleinopathies. In this re- PUFAs; and (3) the soluble oligomerization process is
reversible, in that there is inhibition and apparent disas-gard, we document abnormally elevated amounts of
both soluble and gel-excluded forms of lipid-associated sembly of oligomers when S-expressing cells are ex-
posed to physiological levels of saturated FAs.S in PD and DLB brains (Figure 7).
Of direct relevance to our findings is the recent report It is likely that the accumulation of soluble oligomers
beyond a certain level becomes harmful for neurons. Inthat purified human S oligomerized in the presence of
phospholipid vesicles that contained long-chain PUFAs the three systems we examined here, we found support
for the hypothesis that the time-dependent accumula-and that this was detected as early as 12 hr after adding
the vesicles (Perrin et al., 2001). However, in this in vitro tion of first soluble and then insoluble oligomers is harm-
ful and that neurons use a mechanism of aggregatingstudy, S assembly state was not altered by a PUFA
(arachidonic acid [AA; 20:4]) at physiological concentra- S oligomers that are potentially cytotoxic. First, in sta-
bly S-transfected MES neurons, there was loss of Stions, only at a very high concentration (1000 M) that
is above the critical micelle concentration (20 M) of AA expression shortly after the cells accumulated high lev-
els of soluble oligomers (Figure 5C). Second, in mouse(Richieri et al., 1992). In our experiments, oligomerization
of pure S was observed at concentrations as low as brains, lipid-associated soluble oligomer levels rose
with age, associated with the appearance of gel-10 M for DHA. Indeed, the lowest concentration of AA
we tested in our in vitro oligomerization studies was excluded, insoluble S aggregates (Figures 6A and 6B).
Third, in human brains, both the soluble oligomers found10 M, and this effectively induced S oligomerization
(data not shown). The discrepancy may be due to differ- in the high-speed cytosols and the insoluble oligomers
found in the lipid-rich floating fraction were detected inences in the detection protocols. For example, we in-
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Conditioning Living Cells with FAssubstantially higher levels in ten synucleinopathy than
Subconfluent (75%) cultures of MES cells expressing human wtin five control subjects. In this regard, we have recently
S were cultured in DMEM containing the essential nutrients fordetected a positive correlation between the accumula-
MES cells (Crawford et al., 1992), but without serum. BSA/FA com-
tion of S oligomers in -synucleinopathy brains and plexes were added to the medium just before applying it to the
their cytosolic PUFA levels (R.S. and D.J.S., unpublished cultures. These complexes were prepared by mixing BSA (FA-free;
Sigma) with the indicated FA (at a molar ratio of 1:5) in binding bufferdata). For example, significantly higher levels of DHA
(10 mM Tris HCl [pH 8.0], 150 mM NaCl) at 37C for 30 min. We first(22:6) were observed in PD and DLB than control brains
used 500 M FA and 100 M BSA to prepare the complexes. Later,(p	 0.001). A potential therapeutic corollary of our find-
we used much lower (physiological) concentrations: 35 M FA andings is that the pharmacological regulation of brain lipid
7 M BSA (see Results). Sister cultures, used as controls, were
levels, particularly those of PUFAs, could serve to de- incubated in parallel with BSA but without FA. In the case of experi-
crease the tendency of S, a highly abundant neuronal ments using 13-S-HODE, the ethanol was evaporated under argon
flow to a minimal volume of 100 l. Parallel cultures treated withprotein, to assemble into diffusible oligomers that could
either BSA alone or a BSA-PUFA (18:2) mixture contained ethanolpromote neurotoxicity.
to the same final concentration of 0.3%. The final FA concentration
in this experiment was 100M, which is in the range of FA concentra-Experimental Procedures
tions we found effective (500–35 M). Cells were then collected,
and S370 cytosols prepared as above.Reagents
Fatty acids (sodium salts) were obtained from NU-CHEK PREP, Inc.
(Elysian, MN). Stock solutions (50 mM) were prepared in 10% ethanol
Quantitative Western Blottingin DDW. Aliquots were kept at 20C in the dark under argon. 13-
Quantitative Western blotting was performed as described (SharonS-HODE (in ethanol) was from Cayman Chemicals (Ann Arbor MI),
et al., 2001). Antibodies used were as follows: human S specific,and Lipidex1000 (Hydroxyalkoxypropyl Dextran, Type VI) was from
LB509 (Zymed, San Francisco, CA) and 15G7 (Q Biogene, La Jolla,Sigma (St. Louis, MO).
CA); mouse and human S, H3C (George et al., 1995) and Syn-1
(Transduction Labs, Lexington, KY); and anti-ubiqutin (MBL, Na-Cultured Cells and Transgenic Mice
goya, Japan). In experiments that included heat treatment of PVDFThe rodent mesencephalic neuronal cell line, MES 23.5, which has
membranes, incubation of the blots at 65C for 16 hr in PBS wasdopaminergic properties (Crawford et al., 1992), was maintained
performed right after the protein transfer step.and transfected as described (Sharon et al., 2001). Tg mice (hetero-
zygous) expressing human wt S under the control of the platelet-
derived growth factor B, were kindly provided by Drs. M.S. Goldberg In Vitro Oligomerization
and J. Shen and generated routinely (Sharon et al., 2001). Purified, recombinant human S (gift of Dr. P.T. Lansbury) was re-
suspended in binding buffer (10 mM Tris HCl [pH 8.0], 150 mM NaCl)
Human Brains and incubated with Lipidex1000 (10% w/v) at 37C with rocking for
Frozen tissue samples (control, nondemented cases, n 5; PD, n 30 min. The suspension was spun at 10,000 g and the supernatant
5; DLB, n  5) were obtained from the neuropathology cores of the removed to a clean tube. S protein (2.0 M) was incubated with
Massachusetts Alzheimer Disease Research Center at the Brigham the indicated FAs at indicated concentrations in binding buffer at
and Women’s Hospital, the Massachusetts General Hospital, and 37C for the indicated times. For detection by Western blotting, we
the Massachusetts Institute of Technology, Morris K. Udall Center loaded 75 ng protein, and for detection by silver staining (Invitrogen,
for Excellence in PD Research. All cases were evaluated neuropath- Carlsbad, CA), we loaded 500 ng; these aliquots were from the same
ologically by current diagnostic criteria. Frontal cortex was sampled reaction.
from Broadmann area 8 in the middle frontal gyrus at the level
of the anterior border of the caudate. To calculate p values for
comparisons between controls and PD or controls and DLB, we Isoelectric Focusing
used a t test with 2-tailed, paired distribution. We used the IPGphor isoelectric focusing system (Amersham/Phar-
macia Biotech). High-speed cytosol (10 g protein) was heated at
Fractionation Protocol 65C overnight and brought to 200 l with sample rehydration buffer
A fractionation procedure (Sharon et al., 2001) was used to obtain (7 M urea, 2 M thiourea, 2% Chapso, 0.5% IPG buffer [Amersham
very high-speed cytosols (post-370,000 g 1 hr) of homogenates Pharmacia Biotech], 0.3% DTT, bromophenol blue) and applied on
of MES cells or brain. The same protocol yielded a lipid-rich fraction: an 11 cm 1D ready-strip (Bio-Rad) with a pH gradient of 3–10. The
the initial low-speed (post-170  g  15 min) pellet of the homoge- strip was overlaid with mineral oil to eliminate drying. Sample was
nate was loaded on a 2.15 M sucrose cushion and spun at 60,000 subjected to the following steps: rehydration for 12 hr, isoelectirc
g  1 hr. The lipid-rich fraction is taken from the top of the cushion. focusing at 500 V for 30 min followed by 1000 V for another 30 min
and 8000 V for 7 hr. As focusing proceeded, the current across the
Chloroform/Methanol Extraction of Whole-Mouse Brain strip was dropped to 35 A. The 1D strip was then equilibrated in
The procedure was modified from one used to isolate and purify 10 ml equilibration buffer (50 mM Tris HCl [pH 8.8], 6 M urea, 30%
myelin basic protein from bovine brain (Eylar et al., 1969; Oshiro glycerol, and 10% DTT) for 15 min, applied to a precast 2D SDS-
and Eylar, 1970). Whole-mouse brain (0.5 g) was ground with a PAGE gel (Novax, San Diego CA) and run for 2 hr at 100 V. The
pestle in LN2. Twenty milliliters chloroform/methanol (2:1) were resultant gels were Western blotted as described (Sharon et al.,
added, followed by extensive mixing and addition of 80 ml. After 2001).
rocking 30 min at 4C, the blend was filtered (Whatmann 3 MM
paper). The filtrate was transferred to a clean beaker and 100 ml
fresh chloroform/methanol were added. The blend was rocked at Molecular Weight Estimations of S Oligomers
Human wt S transfected MES cells were incubated overnight in4C for 30 min and filtered again. The chloroform/methanol-soluble
extract (containing lipids) was discarded. The filtered material was DMEM containing the essential nutrients for MES (Crawford et al.,
1992) but without serum. Medium was supplemented with 0.1 mMcompletely evaporated (4 hr) and extracted in 10 ml of 0.01 N NaOH
(pH 11), for 20 hr at 4C. The extract was spun at 10,000  g for 10 BSA (FA free). High-speed cytosols were prepared (above), analyzed
by Western blotting, and scanned by Umax Magic Scan (Eastmanmin. The clear supernatant was transferred to a clean tube and
neutralized with Tris HCl (pH 8.0). The resultant precipitate was Kodak). The relative migration of S-specific bands was analyzed
with a standard BenchMark prestained protein ladder (Invitrogene)removed by centrifugation, and the supernatant transferred to a
clean tube. Protein concentration determined by the Bradford pro- using the AlphaEase version 5.5 software (Alpha Innotech Corp.,
San Leandro, CA)cedure (Bradford, 1976).
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Size Exclusion Chromatography Hamilton, J.A. (1999). Transport of fatty acids across membranes
by the diffusion mechanism. Prostaglandins Leukot. Essent. FattyBed volumes of 40 ml of Sephadex G-75 superfine gel (Amersham
Pharmacia Biotech, Uppsala, Sweden) were packed into borosilicate Acids 60, 291–297.
Econo-columns (Bio-Rad, Hercules, CA). S370 samples (1.5 mg) Hamilton, J.A., and Kamp, F. (1999). How are free fatty acids trans-
from mouse brains or wt-S transfected MES cells, or 1.0 mg of ported in membranes? Is it by proteins or by free diffusion through
purified recombinant S protein, were loaded on the columns. Elu- the lipids? Diabetes 48, 2255–2269.
tion was at a linear flow rate of 15 ml/hr in 50 mM ammonium
Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M., and Masliah,
acetate (pH 7.4), using a peristaltic pump. Fractions (1 ml) were
E. (2001). beta-Synuclein inhibits alpha-synuclein aggregation: a
collected, and 100 l of the indicated fractions were lyophilized,
possible role as an anti-parkinsonian factor. Neuron 32, 213–223.
resuspended in HEPES-MgCl2 buffer, and analyzed by Western blot-
Kahle, P.J., Neumann, M., Ozmen, L., Muller, V., Odoy, S., Okamoto,ting for S.
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